Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose pharmacokinetics, safety, tolerability and antiviral activity of A-831 in male hepatitis C carriers with compensated liver disease
2007-000328-42Phase 2Terminated
- Sponsor
- Arrow Therapeutics
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of A-831 in hepatitis C virus infection, sponsored by Arrow Therapeutics. Primary endpoints: Pharmacokinetic profile of A-831, Antiviral activity of A-831 and 1 more. Started Jun 2007; status: terminated.
02
Drugs
A-831
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2007-000328-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000328-42.